Katherine Baicker joins Lilly board
This article was originally published in Scrip
Lilly has elected Dr Katherine Baicker to its board of directors. Dr Baicker is professor of health economics in the department of health policy and management at the Harvard School of Public Health. She is also a research associate at the National Bureau of Economic Research and an elected member of the Institute of Medicine. She will serve on Lilly's board under interim election and will stand for election by Lilly's shareholders in April 2012.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.